Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP6 | P51161 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.43 |
| ▸ | PARP1 | P09874 | 7/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 6/20 | 0.42 |
| ▸ | PARP11 | Q9NR21 | 5/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 5/20 | 0.38 |
| ▸ | PIM2 | Q9P1W9 | 4/20 | 0.38 |
| ▸ | PLK4 | O00444 | 1/20 | 0.38 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.38 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.38 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.38 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.38 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21999476 | 0.83 | PARP1 (0.54) | FABP6PARP1PARP10PARP11PDPK1 | |
| SCHEMBL20880758 | 0.80 | PARP1 (0.54) | FABP6PARP1PARP10PARP11PDPK1 | |
| SCHEMBL2985573 | 0.80 | PARP1 (0.54) | FABP6PARP1PARP10PARP11PDPK1 | |
| SCHEMBL2983974 | 0.76 | ALPL (0.46) | FABP6PARP1PARP10PARP11NPC1 | |
| SCHEMBL306237 | 0.75 | ADORA2A (0.43) | FABP6EGFRADRA2ANPC1 | |
| SCHEMBL30284433 | 0.75 | ADORA2A (0.43) | FABP6EGFRADRA2ANPC1 | |
| SCHEMBL21461173 | 0.75 | S100A4 (0.42) | FABP6PARP1PARP10PARP11PDPK1 | |
| SCHEMBL1346077 | 0.75 | FABP6 (0.41) | FABP6CYP19A1NPC1 | |
| SCHEMBL21333626 | 0.74 | FABP6 (0.48) | FABP6PARP1PARP10PARP11MAPK1 | |
| SCHEMBL30285422 | 0.74 | FABP6 (0.48) | FABP6PARP1PARP10PARP11MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111825656-B | Inhibitors of protein arginine methyltransferase 5 (PRMT 5), pharmaceutical products thereof, and methods thereof | 南京药石科技股份有限公司 | 2023-03-31 | — | — | CN | claimed |
| CN-111825656-B | Inhibitors of protein arginine methyltransferase 5 (PRMT 5), pharmaceutical products thereof, and methods thereof | 南京药石科技股份有限公司 | 2023-03-31 | — | — | CN | disclosed |
| US-11591326-B2 | Inhibitors of protein arginine methyltransferase 5 (PRMT5), pharmaceutical products thereof, and methods thereof | PHARMABLOCK SCIENCES (NANJING), INC. (CN) | 2023-02-28 | — | — | US | disclosed |
| EP-3761978-A1 | INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | PHARMABLOCK SCIENCES (NANJING), INC. (CN) | 2021-01-13 | — | — | EP | disclosed |
| US-20200399261-A1 | INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | PHARMABLOCK SCIENCES (NANJING), INC. (CN) | 2020-12-24 | — | — | US | disclosed |
| US-20200399261-A1 | INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | PHARMABLOCK SCIENCES (NANJING), INC. (CN) | 2020-12-24 | — | — | US | disclosed |
| CN-111825656-A | Inhibitors of protein arginine methyltransferase 5(PRMT5), pharmaceutical products thereof, and methods thereof | 南京药石科技股份有限公司 | 2020-10-27 | — | — | CN | disclosed |
| WO-2019173804-A1 | INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | PHARMABLOCK SCIENCES (NANJING), INC. (CN) | 2019-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11591326-B2 | Inhibitors of protein arginine methyltransferase 5 (PRMT5), pharmaceutical products thereof, and methods thereof | PRMT5, PRMT1, PRMT3 | FABP6 4477/4885CYP19A1 3360/4885PARP1 351/4885 |
| US-20200399261-A1 | INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | PRMT5, PRMT1, PRMT3 | FABP6 4477/4885CYP19A1 3360/4885PARP1 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.